Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib and Doxil in HER2+ Metastatic Breast Cancer
NCT05748834Phase 2Recruiting
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in breast cancer, sponsored by SCRI Development Innovations. Started Jul 2023; status: recruiting.
02
Drugs
tucatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05748834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748834.